Listed

Tempest Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2013

Filed with the SEC on May 15, 2013 and accepted by EDGAR at May 15, 2013, 13:19 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2013-01-01 to 2013-03-31$2.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-01-01 to 2013-03-31−$5.2mus-gaap:OperatingIncomeLoss
Net income3 months2013-01-01 to 2013-03-31−$5.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2013-01-01 to 2013-03-31−$0.39us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2013-01-01 to 2013-03-31−$4.1mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure3 months2013-01-01 to 2013-03-31$184.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-03-31$43.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-03-31$60.2mus-gaap:AssetsCurrent
Total assetsAt period end2013-03-31$61.2mus-gaap:Assets
Current liabilitiesAt period end2013-03-31$2.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-03-31$2.1mus-gaap:Liabilities
Shareholders' equityAt period end2013-03-31$59.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-13-041862. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.